One to two year treatment of Parkinson's disease with levodopa
- PMID: 5087881
- PMCID: PMC1501971
One to two year treatment of Parkinson's disease with levodopa
Abstract
One hundred patients with Parkinson's disease were treated with levodopa for more than a year at UCLA Medical Center. They were examined at given intervals and their improvement was graded. The optimum therapeutic dose was attained by balancing side effects against relief of symptoms and ranged from 1.5 grams to 8.0 grams per day (average 4.3 grams). There is no doubt that levodopa is the most effective treatment now available for Parkinson's disease. At the end of the first year, 60 percent of the patients improved 50 percent or better, and 10 percent were considered symptom-free. All major symptoms of this disease, including rigidity, akinesia and tremor, improved in variable degree. There were no serious abnormalities in the routine clinical laboratory tests. The comon side effects included nausea, vomiting and choreoathetoid dyskinesias. The side effects were not life threatening, but occasionally were major therapeutic challenges. Maximal benefits with minimal side effects were achieved only by careful adjustments of the levodopa dosage as the months went by. This needed careful management by the physician and cooperation by the patient. Anticholinergic medications or amantadine hydrochloride, sometimes both, usually supplemented the effect of the levodopa.
Similar articles
-
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):422-6. doi: 10.1136/jnnp.37.4.422. J Neurol Neurosurg Psychiatry. 1974. PMID: 4838913 Free PMC article.
-
L-dopa and amantadine hydrochloride in Parkinson's disease.Int Z Klin Pharmakol Ther Toxikol. 1971 Apr;4(3):356-60. Int Z Klin Pharmakol Ther Toxikol. 1971. PMID: 4931417 Clinical Trial. No abstract available.
-
[Initial treatment of Parkinson's disease].Rev Neurol. 1997 Aug;25 Suppl 2:S163-9. Rev Neurol. 1997. PMID: 9280684 Review. Spanish.
-
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.N Engl J Med. 1998 Oct 15;339(16):1105-11. doi: 10.1056/NEJM199810153391603. N Engl J Med. 1998. PMID: 9770557
-
[Treatment of Parkinson's disease with multiple drugs].Nihon Rinsho. 1997 Jan;55(1):59-64. Nihon Rinsho. 1997. PMID: 9014424 Review. Japanese.
Cited by
-
Does levodopa alter depression and psychopathology in Parkinsonism patients?J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):925-35. doi: 10.1136/jnnp.36.6.925. J Neurol Neurosurg Psychiatry. 1973. PMID: 4149286 Free PMC article.
-
Management of parkinson's disease--combined therapy with levodopa and thalamotomy.West J Med. 1975 Jan;122(1):1-6. West J Med. 1975. PMID: 1109524 Free PMC article.
-
Parkinson's disease and levodopa. A five-year follow-up and review.West J Med. 1974 Sep;121(3):188-206. West J Med. 1974. PMID: 4606887 Free PMC article. Review. No abstract available.
-
What Is the Most Important and Impactful Paper Related to Movement Disorder Therapy Published in the 20th Century?Mov Disord Clin Pract. 2021 Sep 21;8(7):993-996. doi: 10.1002/mdc3.13337. eCollection 2021 Oct. Mov Disord Clin Pract. 2021. PMID: 34631934 Free PMC article. No abstract available.
-
Continuous drug delivery in Parkinson's disease.CNS Drugs. 2014 Jan;28(1):19-27. doi: 10.1007/s40263-013-0127-1. CNS Drugs. 2014. PMID: 24323838 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources